A new article published in Biomedicines stated that retinoids, that have numerous applications in inflammatory, dyskeratotic and oncohematology diseases, have now reached the fourth generation—progressively reducing toxicity whilst increasing their efficacy. 

The authors informed that trifarotene – a new fourth-generation retinoid, has a selective action on the retinoic acid receptor gamma (RAR-γ). Randomized trials evaluating the tolerability, safety and efficacy of trifarotene use in dermatological diseases have shown promise. In congenital ichthyosis and acne, this agent have demonstrated great results and mild side effects, and was approved by the FDA for the treatment of lamellar ichthyosis in 2014, and acne vulgaris in 2019. 

It was inferred that trifarotene can be a drug with potential efficacy in the treatment of non-melanoma skin cancers, fungal infections, photoaging and hand-foot skin reactions.

Source: Biomedicines. 2021 Feb 26;9(3):237. doi: 10.3390/biomedicines9030237.